[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562228":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":38,"responsibleParty":53,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":24,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":41,"whyStopped":24,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Queen Mary University of London","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"100% exercise increase","EXPERIMENTAL","Arm: Full-Dose Exercise Group Participants in this arm will be asked to increase their average daily step count by 100% compared with baseline. Using a Fitbit smartwatch and the Slow-SPEED smartphone app, they will receive personalised step goals, real-time feedback, and gamified challenges to encourage gradual and sustained increases in physical activity. The programme is delivered remotely and unsupervised over 18 months, with progress monitored continuously through the wearable device.",[13],"Other: Slow-SPEED app",{"label":15,"type":16,"description":17,"interventionNames":18},"10% exercise increase","ACTIVE_COMPARATOR","Arm: Low-Dose Control Group Participants in this arm will be asked to increase their average daily step count by 10% compared with baseline. Like the intervention group, they will use a Fitbit smartwatch and the Slow-SPEED smartphone app, receiving similar gamified feedback and motivational tools. The lower step target provides an active control condition while maintaining blinding. The programme is delivered remotely and unsupervised over 18 months, with continuous monitoring via the wearable device.",[13],[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"Slow-SPEED app","Gamified motivational smartphone app",[15,9],null,[26],{"name":27,"affiliation":28,"role":29},"Alastair J Noyce, BMedSci, MBBS, MSc, MRCP, PhD","Centre for Preventive Neurology, Queen Mary University of London","PRINCIPAL_INVESTIGATOR",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":24,"email":35},"Viktoria Azoidou, PhD, MSc, BSc","CONTACT","0207 882 3850","v.azoidou@qmul.ac.uk",{"name":27,"role":33,"phone":34,"phoneExt":24,"email":37},"a.noyce@qmul.ac.uk",[39],{"facility":40,"status":41,"city":42,"state":24,"zip":24,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Viktoria Azoidou","RECRUITING","London","United Kingdom","UK",{"type":46,"coordinates":47},"Point",[48,49],-0.12574,51.50853,{"lat":49,"lon":48},[52],{"name":40,"role":33,"phone":24,"phoneExt":24,"email":24},{"type":54,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[56],{"name":57,"class":6},"Radboud University Medical Center","100562228","slow-speed-uk-a-double-blind-randomised-feasibility-trial-100562228",false,"NCT06600438","Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial","Slow-SPEED-United Kingdom: A Double-Blind Randomised Feasibility Trial of a Remote Gamified Physical Activity Programme in Adults With Hyposmia.","Slow-SPEED","Inclusion criteria\n\n* Age ≥ 40 years\n* Objective hyposmia, defined as scoring below the 15th percentile (adjusted for age\u002Fsex) on UPSIT\n* Ability and willingness to provide written informed consent\n* Proficiency in written and spoken English sufficient to complete study procedures.\n* Willingness and ability to attend baseline (in-person), 9-month (remote), and 18-month (in-person) assessments.\n* Access to telephone or internet for interim communication. Specifically, in possession of a suitable smartphone (screen size minimum 4.6 inch; Android version 9 or iOS version 15 or newer).\n* Physical activity threshold: During the 4-week eligibility run-in, the mean daily step count must be \\\u003C7,000 steps\u002Fday, calculated over ≥21 valid days (a valid day = ≥10 hours wear time or ≥1,000 steps). If recruitment after the first 2 months is \\\u003C60-70% of target, and subject to TSC\u002FSponsor approval and REC amendment, eligibility may be broadened to \\\u003C10,000 steps\u002Fday (i.e. participants averaging 7,000-9,999 steps\u002Fday become eligible).\n\nExclusion criteria\n\n* Clinical diagnosis of PD, dementia, or other neurodegenerative conditions\n* Severe or unstable medical or psychiatric illness likely to impair participation\n* Use of agents known to alter olfaction (e.g. intranasal zinc, chronic corticosteroids)\n* Current enrolment in an interventional study within the past 3 months (standard research retention guidance).\n* Inability to complete study procedures in English, per investigator assessment\n* Unable to give consent\n* Participants not living independently in the community. Participants in nursing homes, hospitalised persons on in a non-institutionalised setting are excluded.\n* Subject's personal smartphone is Fitbit-incompatible i.e. Huawei P8 Lite; Huawei P9 Lite; Xiaomi Mi 6; Huawei P20 Lite\n* Activity level above threshold during eligibility run-in: mean daily step count ≥7,000 steps\u002Fday (or ≥10,000 steps\u002Fday if the broadened threshold is activated).","ALL","40 Years","100 Years",{"count":70,"type":71},110,"ESTIMATED","INTERVENTIONAL",[74],"NA","Slow-SPEED UK is an 18-month randomised, double-blind feasibility trial evaluating the delivery, adherence, and acceptability of a digitally supported physical activity programme in community-dwelling adults aged 40 and over with objectively confirmed hyposmia (reduced sense of smell) and low baseline physical activity.\n\nParticipants are randomly assigned 1:1 to either a full-dose activity-support programme (targeting a 100% increase in daily step count) or a very low-dose active control (targeting a 10% increase). Both arms are delivered via a smartphone application linked to a wearable activity monitor (Fitbit Charge 6), with personalised weekly goals expressed as relative percentages to maintain blinding. The study is not designed to test clinical efficacy.",[77,78,79],"Hyposmia","Olfactory Dysfunction","Anosmia",[77,81,82,83,84,85,86],"Physical activity","Feasibility randomized controlled trial","Wearable technology","Smartphone application","Olfactory dysfunction","Digital health intervention","2026-06-24",{"date":89,"type":90},"2026-06-29","ACTUAL",{"date":92,"type":90},"2026-05-27",{"date":94,"type":71},"2027-10-31",{"name":5,"class":6},1]